Differential role of nonhomologous end joining factors in the generation, DNA damage response, and myeloid differentiation of human induced pluripotent stem cells.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 4066476)

Published in Proc Natl Acad Sci U S A on June 02, 2014

Authors

Kerstin Felgentreff1, Likun Du2, Katja G Weinacht3, Kerry Dobbs1, Margarita Bartish2, Silvia Giliani4, Thorsten Schlaeger5, Alexander DeVine5, Axel Schambach6, Lisa J Woodbine7, Graham Davies8, Sachin N Baxi1, Mirjam van der Burg9, Jack Bleesing10, Andrew Gennery11, John Manis12, Qiang Pan-Hammarström2, Luigi D Notarangelo13

Author Affiliations

1: Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115;
2: Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE 14186 Stockholm, Sweden;
3: Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115;Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115;
4: A. Nocivelli Institute for Molecular Medicine, Pediatric Clinic, University of Brescia, Spedali Civili, 25123 Brescia, Italy;
5: Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115;
6: Division of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA 02115;Institute of Experimental Hematology, Hannover Medical School, D-30625 Hannover, Germany;
7: Genome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, United Kingdom;
8: Centre for Immunodeficiency, Great Ormond Street Hospital and Institute of Child Health, London WC1N 3JH, United Kingdom;
9: Department of Immunology, Erasmus Medical Center, 3015 GE, Rotterdam, The Netherlands;
10: Division of Bone Marrow Transplant and Immunodeficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
11: Institute of Cellular Medicine, Pediatric Immunology, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne NE1 4LP, United Kingdom;
12: Department of Transfusion Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115; and.
13: Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115;Harvard Stem Cell Institute, Cambridge, MA 02138 Luigi.Notarangelo@childrens.harvard.edu.

Articles cited by this

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51

The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem (2010) 9.80

Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature (2009) 8.70

A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96

Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell (2002) 6.34

IgH class switching and translocations use a robust non-classical end-joining pathway. Nature (2007) 6.05

Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature (2009) 5.37

Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell (2006) 5.33

DNA repair is limiting for haematopoietic stem cells during ageing. Nature (2007) 4.71

Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev (2009) 4.69

Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer (2008) 4.63

A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41

Regulation of homologous recombination in eukaryotes. Annu Rev Genet (2010) 4.33

Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell (2002) 4.29

DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell (2000) 3.82

ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J (2009) 2.94

DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell (2001) 2.69

Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells. Eur J Immunol (2002) 2.57

The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev (2004) 2.44

Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res (2012) 2.28

Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev (1996) 1.89

A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest (2008) 1.82

DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. PLoS One (2010) 1.75

Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther (2011) 1.69

Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G(2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells (2009) 1.68

Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol (2010) 1.65

The impact of heterochromatin on DSB repair. Biochem Soc Trans (2009) 1.65

DNA-PKcs is critical for telomere capping. Proc Natl Acad Sci U S A (2001) 1.64

Retroviral DNA integration and the DNA damage response. Cell Death Differ (2005) 1.63

DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. Nat Genet (1997) 1.55

Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc Natl Acad Sci U S A (2004) 1.53

Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep (2013) 1.07

PRKDC mutations in a SCID patient with profound neurological abnormalities. J Clin Invest (2013) 1.06

V(D)J recombination deficiencies. Adv Exp Med Biol (2009) 1.02

Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining. Mutat Res (2011) 1.01

Ataxia-telangiectasia mutated (ATM) deficiency decreases reprogramming efficiency and leads to genomic instability in iPS cells. Biochem Biophys Res Commun (2011) 1.01

Human embryonic stem cells are capable of executing G1/S checkpoint activation. Stem Cells (2010) 1.01

A human iPSC model of Ligase IV deficiency reveals an important role for NHEJ-mediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors. Cell Death Differ (2013) 0.99

Radiation-induced delayed cell death in a hypomorphic Artemis cell line. Hum Mol Genet (2006) 0.90

Brief report: a human induced pluripotent stem cell model of cernunnos deficiency reveals an important role for XLF in the survival of the primitive hematopoietic progenitors. Stem Cells (2013) 0.85

Reprogramming and the pluripotent stem cell cycle. Curr Top Dev Biol (2013) 0.81

N-acetylcysteine protects induced pluripotent stem cells from in vitro stress: impact on differentiation outcome. Int J Dev Biol (2012) 0.79